Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9, which plays a key role in transcription regulation. This compound shows promise in oncology for targeting cancer cells by disrupting the transcriptional machinery necessary for tumor growth and survival. It is investigated for its ability to induce apoptosis in hematological malignancies such as leukemia and lymphoma. Its dual action and high selectivity make it a valuable candidate in the development of targeted cancer therapies, especially in cases with resistance to conventional treatments.